Arbovirus Activation And Modulation Of NLRP3 Inflammasome
Funder
National Health and Medical Research Council
Funding Amount
$779,720.00
Summary
This project aims to establish how mosquito borne viruses such as Ross River and dengue viruses interacts with the human host to cause disease, including how the virus evades the host’s immune response to persist and cause disease for prolonged periods. Knowing how differences in the virus and the host’s immune system interplay to cause asymptomatic to severely disabling disease will assist in devising new treatments and prevention programs to lessen the impact of these diseases in Australia.
New Insights Into Viral Inflammatory Disease Mechanisms And Approaches To Therapy
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
This fellowship aims to establish how viruses cause disease, including how they evade the immune response to persist and cause disease for prolonged periods. My vision is that knowing how the virus and the immune system interact to determine disease severity will assist in devising new treatments and prevention programs to lessen the impact of viral diseases in Australia and worldwide.
Mosquito-borne alphaviruses such as Ross River and chikungunya viruses cause widespread epidemics and exert extreme pressure on the public health systems of affected regions. Alphaviruses spreads to joints and triggers a severe disease in those affected. There are no effective treatments or vaccines. The project will investigate virus-host interaction at the bite site. The outcome will be new knowledge to treat infection at the mosquito bite site to prevent joint disease.
Novel Insights Into The Pathobiology Of Alphavirus Infections
Funder
National Health and Medical Research Council
Funding Amount
$827,660.00
Summary
Infections with mosquito-borne viruses are increasing at an alarming rate worldwide. Ross River virus is endemic in parts of Australia, PNG and Pacific islands, while chikungunya virus is distributed globally and causes recurrent pandemics that involve millions of people. These viruses cause severe musculoskeletal disease for several months after infection. This project aims to establish how these viruses interact with the human host to cause disease and may provide a basis for new treatments.
Glycotherapeutics; A New Class Of Treatment For Alphavirus-induced Musculoskeletal Disease
Funder
National Health and Medical Research Council
Funding Amount
$449,868.00
Summary
The hallmark of alphavirus disease is crippling pain and joint arthritis, which often has an extended duration. Currently there is no licenced specific treatment for alphavirus disease and the increasing spread of infection highlights an urgent need for therapeutic intervention strategies. This grant looks at the potential of pentosan polysulfate as a promising drug-repurposing candidate for the treatment of alphavirus-induced arthritis.
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Individualising Care For Patients With Chronic Hepatitis C: Predicting Side Effects And Treatment Response Using Genomic And Proteomic Approaches.
Funder
National Health and Medical Research Council
Funding Amount
$55,575.00
Summary
Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially impro ....Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially improving the safety and efficacy of therapy.Read moreRead less
Population-level Epidemiological Trends In Hepatocellular Carcinoma In Queensland 1996 - 2010.
Funder
National Health and Medical Research Council
Funding Amount
$251,695.00
Summary
Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC t ....Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC trends.Read moreRead less